# US 2012/0251492 A1 · Triterpene derivative and agent for preventing or treating chronic hepatitis c

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251492 A1
- Document ID: US20120251492A1
- Status: Published application
- Kind: A1
- Application number: 13/516,012
- Filed: 2010-12-15
- Published: 2012-10-04
- Earliest claimed: 2009-12-15
- Assignees: Meiji Seika Pharma Co., Ltd.
- Inventors: Makoto Ishikawa; Shigeki Suzuki; Makoto Aoki; Nobuto Minowa; Kokichi Suzuki
- Web page: https://patentgrep.com/patent/US20120251492A1

## CPC

- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A61K 31/12: Ketones
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/14: for RNA viruses
- C07J 63/008: {Expansion of ring D by one atom, e.g. D homo steroids}
- C07J 71/0005: {Oxygen-containing hetero ring}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

Provided are a triterpene derivative represented by a general formula (I), a pharmaceutically acceptable salt thereof, and an agent for preventing or treating chronic hepatitis C comprising the triterpene derivative or the salt as an active ingredient: [in the formula (I), R1 represents a carboxyl group, a hydroxymethyl group, —CH2OSO3H, or and R2 represents —OR3 or —O— (CH2) m-OR4, where R3 represents a benzyl group which may be substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or a hydroxy C1-6 alkyl group, R4 represents a phenyl group which may be substituted with a carboxyl group, and m represents an integer of 1 to 3, with the proviso that a case where R1 is —CH2OH, and R3 is a C1-6 alkyl group, a C2-6 alkenyl group, or a benzyl group is excluded].

## Claims

### Claim 1

A triterpene derivative represented by a general formula (I) or a pharmaceutically acceptable salt thereof:
[in the formula (I), R1 represents a carboxyl group, a hydroxymethyl group, —CH2OSO3H, or
and R2 represents —OR3 or —O—(CH2)m—OR4, where R3 represents a benzyl group which may be substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or a hydroxy C1-6 alkyl group, R4 represents a phenyl group which may be substituted with a carboxyl group, and m represents an integer of 1 to 3, with the proviso that a case where R1 is a hydroxymethyl group, R2 is —OR3, and R3 is a C1-6 alkyl group, a C2-6 alkenyl group, or a benzyl group is excluded].

### Claim 2

A triterpene derivative represented by a general formula (I) or a pharmaceutically acceptable salt thereof:
[in the formula (I), R1 represents a carboxyl group, and R2 represents —OR3, where R3 represents a benzyl group, a methyl group, or an allyl group].

### Claim 3

A triterpene derivative represented by a general formula (I) or a pharmaceutically acceptable salt thereof:
[in the formula (I), R1 represents a hydroxymethyl group, and R2 represents —OR3 or —O—(CH2)3—OR4, where R3 represents a benzyl group substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a 2-propynyl group, a 3-hydroxypropyl group, or a 2-hydroxypropyl group, and R4 represents a phenyl group or a phenyl group substituted with a carboxyl group].

### Claim 4

A triterpene derivative represented by a general formula (I) or a pharmaceutically acceptable salt thereof:
[in the formula (I), R1 represents —CH2OSO3H, and R2 represents a methoxy group].

### Claim 5

A triterpene derivative represented by a general formula (I) or a pharmaceutically acceptable salt thereof:
[in the formula (I), R1 represents
and R2 represents a methoxy group].

### Claim 6 (depends on 1)

The triterpene derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein an IC50 value of inhibitory activity against hepatitis C virus is 20 μM or less.

### Claim 7 (depends on 1)

An agent for preventing or treating chronic hepatitis C, comprising the triterpene derivative according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 8 (depends on 7)

The agent according to claim 7, comprising a pharmaceutically acceptable carrier.

### Claim 9 (depends on 7)

The agent according to claim 7, further comprising an interferon in combination.

### Claim 10 (depends on 7)

A method for preventing or treating chronic hepatitis C, comprising administering the agent claim 7 in a prophylactically or therapeutically effective amount to a patient who needs prevention or treatment of chronic hepatitis C.

### Claim 11 (depends on 1)

Use of the triterpene derivative or the pharmaceutically acceptable salt according to claim 1, for producing an agent for preventing or treating chronic hepatitis C.

### Claim 12 (depends on 11)

The use according to claim 11, wherein the agent for preventing or treating chronic hepatitis C comprises a triterpene derivative represented by a general formula (I) or a pharmaceutically acceptable salt thereof:
[in the formula (I), R1 represents a carboxyl group, a hydroxymethyl group, —CH2OSO3H, or
and R2 represents —OR3 or —O—(CH2)m—OR4, where R3 represents a benzyl group which may be substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or a hydroxy C1-6 alkyl group, R4 represents a phenyl group which may be substituted with a carboxyl group, and m represents an integer of 1 to 3, with the proviso that a case where R1 is a hydroxymethyl group, R2 is −OR3, and R3 is a C1-6 alkyl group, a C2-6 alkenyl group, or a benzyl group is excluded].

### Claim 13 (depends on 1)

The triterpene derivative or the pharmaceutically acceptable salt according to claim 1, for use in prevention or treatment of chronic hepatitis C.
